Germany’s Bayer is examining China-based production units of Polish insulin maker Bioton as it is interested in cooperation between the two companies, daily Parkiet reported on Monday.
“Many companies are looking close at us, Bayer is one of them,” the chief executive of Bioton, Janusz Guy told Parkiet.
Bayer Schering Pharma, Bayer’s drugmaker arm, said last week it was confident of revenue growth between 17-19% this year in the Asia-Pacific and that it was expanding output in China.
The drugmaker, which aims to double Asia-Pacific revenue over the next five years, achieved 23% revenue growth last year in Asia, the fastest-growing region of its pharmaceutical business, driven by growth of more than 50% in China. (Reuters)